Lv4
498 积分 2021-12-30 加入
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
17天前
已完结
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
1个月前
已完结
Tumour heterogeneity and resistance to cancer therapies
1个月前
已完结
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
1个月前
已完结
Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway
1个月前
已完结
Structure-guided discovery of a potent 4th-generation EGFR-TKI overcoming osimertinib-resistant C797S
1个月前
已完结
The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability
1个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
1个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2个月前
已完结
皖公网安备34019202002308
